Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Matters Arising
  • Published:

Reply to: Comparator choices in pharmacoepidemiology studies of Alzheimer’s disease

Nature Aging volume 3, pages 793–795 (2023)Cite this article

Subjects

The Original Article was published on 22 May 2023

replying to Q. L. Her et al. Nature Aging https://doi.org/10.1038/s43587-023-00417-x (2023)

Her and colleagues raise issues concerning best practices for pharmacoepidemiological studies1. Here we provide details that allow more insights into our choices.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Her, Q. L., Kahrs, J. C. & Sturmer, T. Comparator choices in pharmacoepidemiology studies of Alzheimer’s disease. Nat. Aging https://doi.org/10.1038/s43587-023-00417-x (2023).

  2. Galiè, N. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 37, 67–119 (2016).

    Article  PubMed  Google Scholar 

  3. Fang, J. et al. Endophenotype-based in silico network medicine discovery combined with insurance records data mining identifies sildenafil as a candidate drug for Alzheimer’s disease. Nat. Aging 1, 1175–1188 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cummings, J. et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement. 8, e12295 (2022).

    Google Scholar 

  5. Lund, J. L., Richardson, D. B. & Stürmer, T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr. Epidemiol. Rep. 2, 221–228 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  6. D’Arcy, M., Stürmer, T. & Lund, J. L. The importance and implications of comparator selection in pharmacoepidemiologic research. Curr. Epidemiol. Rep. 5, 272–283 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Gong, B. et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int. Urol. Nephrol. 49, 1731–1740 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Garcia-Barroso, C. et al. Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology 64, 114–123 (2013).

    Article  CAS  PubMed  Google Scholar 

  9. Zhang, P. et al. Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer’s disease in African Americans. Alzheimers Dement. https://doi.org/10.1002/alz.12819 (2022).

  10. Charpignon, M.-L. et al. Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia. Nat. Commun. 13, 7652 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585 (2013).

    Article  CAS  Google Scholar 

  12. Heckman, P. R. A., Blokland, A. & Prickaerts, J. From age-related cognitive decline to Alzheimer’s disease: a translational overview of the potential role for phosphodiesterases. Adv. Neurobiol. 17, 135–168 (2017).

    Article  PubMed  Google Scholar 

  13. Zhang, J. et al. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav. Brain Res. 250, 230–237 (2013).

    Article  CAS  PubMed  Google Scholar 

  14. Samudra, N. et al. A pilot study of changes in medial temporal lobe fractional amplitude of low frequency fluctuations after sildenafil administration in patients with Alzheimer’s disease. J. Alzheimers Dis. 70, 163–170 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sheng, M. et al. Sildenafil improves vascular and metabolic function in patients with Alzheimer’s disease. J. Alzheimers Dis. 60, 1351–1364 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN, USA

    Pengyue Zhang

  2. Genomic Medicine Institute Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

    Yuan Hou & Feixiong Cheng

  3. Department of Biomedical Informatics, College of Medicine, Ohio State University, Columbus, OH, USA

    Chien-Wei Chiang

  4. Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA

    Andrew A. Pieper

  5. Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA

    Andrew A. Pieper

  6. Geriatric Psychiatry, Geriatric Research Education and Clinical Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH, USA

    Andrew A. Pieper

  7. Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, USA

    Andrew A. Pieper

  8. Department of Neuroscience, Case Western Reserve University, School of Medicine, Cleveland, OH, USA

    Andrew A. Pieper

  9. Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA

    Jeffrey Cummings

  10. Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA

    Feixiong Cheng

Authors
  1. Pengyue Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuan Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chien-Wei Chiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew A. Pieper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeffrey Cummings
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Feixiong Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

F.C. and P.Z. drafted the manuscript. F.C., P.Z., Y.H., C.W.-C., A.A.P. and J.C. revised and approved this reply manuscript.

Corresponding author

Correspondence to Feixiong Cheng.

Ethics declarations

Competing interests

J.C. has provided consultation to Acadia, Actinogen Medical, Alkahest, Alzheon, Annovis Bio, Avanir Pharmaceuticals, Axsome Therapeutics, Biogen, BioXcel Therapeutics, Cassava Sciences, Cerecin, Cerevel Therapeutics, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight Pharmaceuticals, GemVax, Genentech, Green Valley, Grifols, Karuna Therapeutics, Merck, Novo Nordisk, Otsuka Pharmaceuticals, Resverlogix, Roche, Biosplice Therapeutics (formerly) Samumed, Samus Therapeutics, Signant Health, Suven Life Sciences, Third Rock Ventures and United Neuroscience. J.C. has stock options in Adamas Pharmaceuticals, Annovis Bio, MedAvante and Bioasis Technologies. The remaining authors declare no competing interests.

Peer review

Peer review information

Nature Aging thanks Emre Guney, Heather Allore, Jennifer Weuve and Kevin Wing for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, P., Hou, Y., Chiang, CW. et al. Reply to: Comparator choices in pharmacoepidemiology studies of Alzheimer’s disease. Nat Aging 3, 793–795 (2023). https://doi.org/10.1038/s43587-023-00418-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43587-023-00418-w

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing